INTRODUCTION

Concurrent with improvements in living standards and changes in living habits, the global incidence of diabetes has been increasing yearly. Several diabetes-related complications, including diabetic osteoporosis, pose severe threats to the well-being of people with diabetes. Although the pathogenesis of diabetic osteoporosis is unclear, recent studies have suggested it may be related to the influence of a high-glucose environment on metabolism, subsequently affecting bone formation, and may be realized through gene polymorphism changes. Diabetic osteoporosis may also be caused by excessive reactive oxygen species (ROS) production and advanced glycation end products. In addition, hyperglycaemia can promote the nonenzymatic glycosylation of diverse bone proteins.

Melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev-Erbα in osteoblasts

Yihao Tian | Jian Ming

Department of Pathology, General Hospital of Northern Theater Command, Shenyang, China

Correspondence
Jian Ming, Department of Pathology, General Hospital of Northern Theater Command, Shenyang, China. Email: mjjgc7878@163.com

Abstract
Diabetic osteoporosis is secondary osteoporosis and a serious complication of diabetes with a high incidence rate and poor prognosis. The specific mechanism of diabetic osteoporosis is unclear, and prevention and treatment options are limited. Recently, melatonin has been found to prevent and treat diabetic osteoporosis. Herein, we investigated the mechanism whereby melatonin inhibits osteoclastogenesis and identified a new target for osteoporosis treatment. We established an in vitro osteoblast-osteoclast co-culture system as a diabetic osteoporosis model. Osteoclastogenesis was determined using tartrate-resistant acid phosphatase staining and cathepsin K expression. Real-time PCR was used to ascertain expression of microRNA mir-882, targeting Rev-Erbα. Western blotting was performed to detect the expression of Rev-Erbα, receptor activator of NF-κB ligand (RANKL), and osteoprotegerin (OPG), and ELISA was utilized to analyse the secreted form of RANKL. High glucose promoted osteoclastogenesis and elevated the RANKL/OPG ratio in osteoblasts, while melatonin reversed these effects. High glucose inhibited Rev-Erbα expression, while melatonin promoted its expression. Conversely, high glucose promoted mir-882 expression, while melatonin inhibited it. We infer that melatonin inhibits RANKL expression in osteoblasts via the mir-882/Rev-Erbα axis, thus inhibiting osteoclastogenesis. Our findings provide insights into diabetic osteoporosis and identify a new therapeutic target for osteoporosis.

KEYWORDS
co-culture, diabetic osteoporosis, melatonin, mir-882, osteoclastogenesis, rev-Erbα

1 | INTRODUCTION

Concurrent with improvements in living standards and changes in living habits, the global incidence of diabetes has been increasing yearly. Several diabetes-related complications, including diabetic osteoporosis, pose severe threats to the well-being of people with diabetes. Although the pathogenesis of diabetic osteoporosis is
matrix proteins, such as type I collagen, resulting in bone damage. Moreover, insulin promotes osteoblast growth, as the osteoblast surface contains insulin receptors; however, insulin levels decrease in diabetic patients, affecting osteoblast growth. Diabetes may also cause calcium loss, with low blood calcium levels leading to secondary hyperparathyroidism, activating osteoclasts. Furthermore, diabetes can lead to peripheral blood vessel disease, neuropathy, and kidney disease, among other disorders, as precursors of osteoporosis. Kidney damage caused by diabetes can result in decreased hydroxylase activity, leading to reduced vitamin D levels. There are currently no specific drugs for the treatment of diabetic osteoporosis; however, recent studies have demonstrated potency of melatonin in hampering and treating diabetic osteoporosis.

Melatonin has been more consistently shown to be anabolic in multiple studies using mouse genetic models and also physiological doses of melatonin. Melatonin is a rhythmically secreted hormone important for maintaining normal circadian rhythm in organisms. In organisms, several clock genes encode clock or rhythm proteins, including Clock/Bmal complex, Per/Cry complex, Rev-erb and Ror. Clock/Bmal complex and Ror are positive circadian clock regulators, while Per/Cry complex and Rev-erb are negative regulators. The positive and negative regulatory factors form a feedback loop and regulate each other to maintain normal biological clock rhythm. Rev-erb is also a nuclear transcription inhibitor that exerts biological effects by inhibiting transcription. Rev-erb, in both its α and β forms, is considered an orphan receptor as no endogenous ligand in vivo has been identified. Rev-erb is expressed in adipose tissues, bones and muscles, and several studies have confirmed that it has diverse functions. For example, Rev-erb is involved in cell metabolism, gene transcription and other physiological processes, as well as pathological processes, such as renal carcinoma, glioblastoma multiforme, autoimmune diseases and hepatitis. The effect of melatonin on bone mass varies under diabetic osteoporosis conditions. Exogenous melatonin can prevent type 1 diabetes mellitus-induced bone loss by inhibiting senescence. Melatonin can also suppress ferroptosis induced by high glucose via activation of the Nrf2/HO-1 signalling pathway in type 2 diabetic osteoporosis.

Healthy bone in organisms depends on a dynamic equilibrium between bone production by osteoblasts and bone absorption by osteoclasts. Disturbance of this balance results in bone diseases, with increased bone formation leading to osteosclerosis and increased bone resorption leading to osteoporosis. Osteoblasts and osteoclasts regulate and interact with each other through both direct contact and paracrine signalling. Receptor activator of NF-κB ligand (RANKL), osteoprotegerin (OPG) and other factors secreted by osteoblasts act on osteoclasts and regulate their proliferation and differentiation. RANK expressed on the surface of osteoclasts receives information from osteoblasts by binding to RANKL. At the same time, osteoclasts can act on osteoblasts through ATPase H+Transporting V0 Subunit D2 (ATP6V0D2), complement component 3a, signal transducer 4D, or microRNA. Therefore, establishing an in vitro osteoblast-osteoclast co-culture system as a model to simulate the in vivo environment is useful to study the mechanisms related to osteoporosis and other bone diseases. This approach can provide results that are easily translated to clinical settings. In the current study, we assessed the biological function of Rev-erb in bone tissue with respect to inhibition of osteoclastogenesis and explored the specific underlying mechanisms.

2 | MATERIALS AND METHODS

2.1 | Cell culture

The osteoblastic MC3T3-E1 and macrophage-like RAW264.7 murine cell lines were obtained from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. The MC3T3-E1 cells were cultured in α-MEM medium containing 10% serum and 1% penicillin/streptomycin (HyClone, GE Healthcare). The RAW264.7 cells were cultured in DMEM containing 10% serum and 1% penicillin/streptomycin (HyClone, GE Healthcare). All cells were incubated at 37°C in an incubator with 95% air, 5% carbon dioxide and maximum humidity. Culture media were changed every day, and the cells were passaged every 2 days. MC3T3-E1 cells were trypsinized before passage, and RAW264.7 cells were aspirated and transferred using a pipette without trypsin digestion. The cells were starved for 24 h in serum-free media before the experiments were performed.

2.2 | Osteoblast/osteoclast co-culture

The co-culture system was established using a Transwell chamber separated by a 0.4 μm polyethylene terephthalate (PET) membrane. MC3T3-E1 and RAW264.7 cells were placed in the lower and upper layers of the chamber, respectively, at a 5:1 ratio. The cells were cultured in α-MEM containing 10% serum and 1% penicillin/streptomycin at 37 °C with 95% air, 5% carbon dioxide and maximum humidity. Then, 30 ng/mL RANKL (R&D Systems, Inc. USA) and 10 ng/mL macrophage colony-stimulating factor (M-CSF; R&D Systems, Inc.) were added to initiate osteoclast differentiation.

First, the use of high glucose alone without the assistance of RANKL and M-CSF could not produce sufficient concentration of RANKL to induce osteoclast differentiation. Second, RANKL measured by Enzyme-linked immunosorbent assay (ELISA) is not always released by osteoblasts, and some of them are exogenous. However, the same concentration of exogenous RANKL was added in each group in advance, so that the final observation index is the trend of differences between groups.

Osteoblasts were transfected first. After 6–8 h, the fluid was changed and then co-cultured with osteoclasts. There may be any direct effect of the above axis on osteoclast/precursors. This study...
mainly focuses on the changes in RANKL/OPG, and it is known, that RANKL/OPG promotes osteoclastogenesis. Although osteoclastogenesis may be directly affected by melatonin, this study detected the most important inducing factor in the early stage of osteoclastogenesis, RANKL/OPG. Therefore, even if it directly affects osteoclast/precursors, the result of osteoclastogenesis is the superposition of RANKL/OPG and direct effect.

2.3 | RNA oligonucleotide synthesis and transfection

MicroRNA (miRNA) mir-882 mimics, mir-882 negative control (NC), mir-882 inhibitor and mir-882 inhibitor NC were purchased from Shanghai GenePharma Pharmaceutical Technology Co., Ltd. MC3T3-E1 cells were transfected with the mimics, inhibitors or NCs using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), and successfully transfected cells were then co-cultured with RAW264.7 cells.

2.4 | Cell counting kit (CCK)-8 assay

MC3T3-E1 cells were seeded into 96-well plates (5 × 10^3 cells/well). After incubating for 24 h to allow cell adhesion, 1, 10, and 100 μM melatonin (Sigma-Aldrich, Merck KGaA), 5, 10, and 15 μM sr9009 (MedChemExpress, Monmouth Junction), or 5, 10, and 15 μM sr8278 (MedChemExpress) were added to the cells. Cellular activity was assessed 48 h post-treatment using the CCK-8 assay (Dojindo Molecular Technologies, Inc.) according to the manufacturer’s instructions. Formazan was measured at 450 nm using an ELx808 microplate reader (BioTek Instruments, Inc.) and quantified as an optical density (OD) value.

2.5 | Tartrate-resistant acid phosphatase (TRAP) staining

RAW264.7 cells in the upper Transwell chamber were washed several times with phosphate-buffered saline (PBS) after discarding the spent culture medium and then fixed with paraformaldehyde at 37°C for 15 min. TRAP staining was then performed according to the manufacturer’s instructions (Sigma-Aldrich; Merck KGaA; cat. no. 387). Briefly, TRAP working solution was added after the fixative was removed and the cells were incubated for 60 min in a water bath at 37°C. The staining solution was then discarded, and the cells were washed twice with PBS. Thereafter, the cell nuclei were stained with haematoxylin for 10 min, and cells were washed twice with PBS. Cell images were acquired using a fluorescence electron microscope (Nikon Corporation; magnification, 200x and 400x). Cells containing three or more nuclei were considered TRAP-positive osteoclasts.

2.6 | Western blotting

Treated cells were placed on ice and lysed with RIPA buffer containing 1% phenylmethanesulfonyl fluoride (PMSF; Beyotime Institute of Biotechnology, China) for 30 min. The lysed samples were centrifuged at 12,000 × g for 30 min at 4°C. A bicinchonic acid (BCA) kit (Beyotime Institute of Biotechnology) was used to quantify the protein and 3 μg/μL of protein was loaded onto a 10% resolving gel and separated by sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) at a constant voltage of 80 V. The separated proteins were transferred to polyvinylidene fluoride (PVDF) membrane at a constant current of 200 mA for 1 h. The membrane was blocked with 5% bovine serum albumin (BSA) for 2 h at 25°C and then incubated with the relevant primary antibodies at 4°C overnight. The following primary antibodies were used: Anti-cathepsin K (cat. no. ab19027, 1:1000; Abcam), anti-nuclear receptor subfamily 1 group D member 1 (NR1D1/Rev-Erb; cat. no. ab174309, 1:5000; Abcam), anti-RANKL (cat. no. ab45039, 1:500; Abcam), anti-OPG (cat. no. ab203061, 1:300; Abcam), and anti-GAPDH (cat. no. 10494-1-AP, 1:10,000; ProteinTech Group, Inc.). The membrane was washed three times using tris-buffered saline with 0.1% Tween 20 (TBST) and incubated with the secondary antibody (1:10,000; ProteinTech Group, Inc.) at 25°C for 2 h. The membrane was washed three times with TBST and developed using luminescent solution (cat. no. PK10002; ProteinTech Group, Inc.). The protein bands were observed using a MicroChem bioimaging system (DNIR Imaging Systems Ltd.). Image J software (v1.52; National Institutes of Health) was used to measure the grey value and quantify the results.

2.7 | RNA extraction and real-time polymerase chain reaction (PCR)

Processed cells were placed on ice and washed with PBS three times. Total RNA was extracted using Trizol reagent according to the manufacturer’s instructions. The mRNA was reverse transcribed using the PrimeScript RT Reagent Kit with gDNA Eraser (RR047A; Takara Biotechnology Co., Ltd.). The miRNA was reverse transcribed using the Mir-X miRNA qRT-PCR TB Green® Kit (638,314; Clontech). Real-time PCR was performed using an SYBR Green Kit and a Roche Light Cycler® 480 II system (Roche Diagnostics). The relative expression of mRNA was analysed using GAPDH as an internal reference. The relative expression of target miRNA was analysed using U6 as an internal reference. Gene expression was calculated using the 2^−ΔΔCT method.

2.8 | Enzyme-linked immunosorbent assay

Post-treatment, the cell supernatant was stored and centrifuged to remove cell debris. Secreted RANKL in the supernatant was detected
using ELISA kits (R&D Systems, Inc.) according to the manufacturer’s instructions. The absorbance was measured at 450 nm using an ELISA microplate reader. The concentration of secreted RANKL was determined using a standard curve.

2.9 | Enrichment analysis and transcription factor-promoter prediction

The MiRNA Enrichment Analysis and Annotation database (https://ccb-compute2.cs.uni-saarland.de/mieaa2/user_input/) was used to analyse the relevant biological processes and pathways of miRNAs which could all take Rev-Erbα as target genes. Potential transcription factors that could target RANKL were predicted by using the databases UCSC (http://genome.ucsc.edu/) and JASPAR (https://jaspar.genereg.net/) and organizing and consolidating these data.

2.10 | Statistical analysis

SPSS software (IBM Corp.) and PRISMA software (GraphPad Software, Inc.) were used for data analysis. Results are expressed as the mean ± standard deviation of three independent experiments. Comparison between two groups was made by t-test, and comparison between multiple groups was conducted by post-analysis of variance (ANOVA). Results with \( p < 0.05 \) were considered statistically significant.

3 | RESULTS

3.1 | Melatonin inhibited high glucose-induced osteoclastogenesis of RAW264.7 cells

To study the effect of melatonin on osteoclastogenesis using the co-culture system, we evaluated the mRNA and protein expression...
of cathepsin K (Figures 1A, B). The expression of cathepsin K at both the mRNA and protein levels increased in RAW264.7 cells treated with high glucose (25 mmol/L)35,36; however, these decreased after treatment with 0.1 and 1 μM melatonin. We then studied osteoclastogenesis using TRAP staining 48 h after melatonin treatment (Figure 1C). At high glucose concentrations, more TRAP-positive cells were observed in the osteoblast–osteoclast co-culture system; however, the number decreased after melatonin treatment. We also assessed the cytotoxicity of melatonin using a CCK-8 assay (Figure 1D). The results showed that melatonin was not cytotoxic to MC3T3-E1 or RAW264.7 cells, even after 48 h of treatment. However, melatonin significantly inhibited high glucose-induced osteoclastogenesis of RAW264.7 cells in the co-culture system.

**FIGURE 2** In the co-culture system, melatonin upregulates the expression of OPG and decreases the expression and secretion of RANKL. The expression (A) and secretion (B) of RANKL and OPG in MC3T3-E1 cells cultured for 7 days with RANKL (30 ng/mL) and M-CSF (10 ng/mL) with high glucose in the presence of varying concentrations (0.1 or 1 μmol/L) of melatonin. Data are represented as the mean ± SD (n = 3). **p < 0.01. OPG, Osteoprotegerin; RANKL, receptor activator of nuclear factor κB ligand; M-CSF, macrophage colony-stimulating factor.**
3.2 | Melatonin inhibited RANKL/OPG expression and secretion in osteoblasts

RANKL and OPG expressed and secreted by osteoblasts are closely associated with osteoclastic differentiation. The status of RANKL and OPG in osteoblasts and the cell supernatant of the co-culture system were analysed post-high-glucose treatment by performing western blotting and ELISA, respectively. We determined that high glucose (25 mmol/L) promoted the expression and secretion of RANKL but inhibited the expression of OPG (Figure 2A,B). After 0.1 and 1 μM melatonin treatment for 48h, the expression and secretion of RANKL decreased, while expression of OPG increased (Figure 2A,B).

3.3 | Melatonin increased Rev-Erbα expression in MC3T3-E1 cells

During high glucose-induced osteoclast differentiation of RAW264.7 cells, mRNA, and protein expression levels of Rev-Erbα in MC3T3-E1 cells were inhibited. However, 0.1 and 1 μM melatonin treatment significantly increased Rev-Erbα expression at both the mRNA and protein levels (Figure 3A,B).

3.4 | Rev-Erbα activation enhanced the inhibitory effect of melatonin on osteoclastogenesis

The Rev-Erbα agonist sr9009 and antagonist sr8278 were used in the co-culture system to evaluate the effect of melatonin on MC3T3-E1 cells and on osteoclast differentiation of RAW264.7 cells after high glucose treatment. Consistent with previous studies, we found that neither sr9009 nor sr8278 had cytotoxic effects on MC3T3-E1 cells after treatment for 48h, as evaluated using the CCK-8 assay (Figure 4A,B). Western blotting results showed that melatonin inhibited osteoclastogenesis more significantly in MC3T3-E1 cells treated with Rev-Erbα agonist sr9009 than without sr9009 (Figure 4C), while Rev-Erbα antagonist sr8278 produced the opposite effect (Figure 4D).

3.5 | Rev-Erbα activation suppressed RANKL/OPG expression and secretion

The Rev-Erbα agonist sr9009 and antagonist sr8278 were also used in the co-culture system to evaluate the effect of Rev-Erbα on the expression and secretion of RANKL and OPG in high glucose-treated MC3T3-E1 cells. Western blotting and ELISA results revealed that
Melatonin significantly suppressed RANKL and OPG expression and secretion from MC3T3-E1 cells treated with SR9009 compared to that of control cells (Figure 5A,B), while SR8278 induced the opposite effect (Figure 5C,D).

3.6 Mir-882 exerted its effects through Rev-Erbα

Rev-Erbα, as a target gene of mir-882, has been shown in previous studies to mediate some of the biological effects of mir-882, such as inhibiting osteoclastogenesis. Accordingly, we transfected MC3T3-E1 cells with mir-882 mimics, inhibitors, or NC (Figure 6A), co-cultured these with RAW264.7 cells, and then evaluated the expression of mir-882 and Rev-Erbα. The results indicated the level of mir-882 expression in MC3T3-E1 cells was significantly higher in mir-882 mimic-treated cells than that in NC cells. In contrast, the expression of mir-882 was lower in mir-882 inhibitor-treated MC3T3-E1 cells than that of NC cells. We examined the expression of Rev-Erbα to determine whether it was regulated by mir-882 (Figure 6B). Transfection of MC3T3-E1 cells with mir-882 mimics
significantly reduced the expression level of Rev-Erbα protein in MC3T3-E1 cells, while inhibition of mir-882 had the opposite effect.

3.7 | Melatonin downregulated mir-882 expression and mir-882 inhibition suppressed osteoclastogenesis

Since mir-882 targeted Rev-Erbα expression in MC3T3-E1 cells, we further explored its influence on osteoclastogenesis. To elucidate the role of mir-882 in melatonin-mediated inhibition of high glucose-induced osteoclastogenesis, we evaluated the expression of mir-882 in MC3T3-E1 cells using real-time PCR (Figure 7A). The results indicated that melatonin reduced the expression of mir-882 after high glucose (25 mmol/L) treatment. Next, we transfected MC3T3-E1 cells with mir-882 mimics, inhibitors, or NCs, co-cultured the transfected cells with RAW264.7 cells, and then evaluated the expression of cathepsin K in the RAW264.7 cells. Compared with that of NC-transfected cells, overexpression of mir-882 increased the expression of cathepsin K, while transfection with mir-882 inhibitors decreased the expression of cathepsin K (Figure 7B). This suggested that mir-882 inhibition may inhibit osteoclastogenesis.

3.8 | mir-882 inhibition suppressed RANKL/OPG expression and secretion

We further explored the capability of mir-882 to modulate the expression and secretion of RANKL/OPG, thereby affecting osteoclastogenesis. We transfected MC3T3-E1 cells with mir-882 mimics, inhibitors, or NCs, co-cultured the transfected cells with RAW264.7 cells, and after that examined the expression and secretion of RANKL/OPG from the transfected MC3T3-E1 cells (Figure 8A,B). The results showed that transfection with mir-882 mimics increased RANKL/OPG expression and secretion in MC3T3-E1 cells, while mir-882 inhibitors decreased expression and secretion. Collectively, our results showed that downregulation of mir-882 in MC3T3-E1 cells hindered osteoclastogenesis, while mir-882 overexpression may promote osteoclastogenesis.

3.9 | Rev-Erbα regulates Rankl expression via indirect binding to the Rankl promoter

Rev-Erbα reportedly regulates the expression of various target genes as a transcription factor repressor; therefore, it is likely that its inhibition of osteoclastogenesis occurs through the deactivation of downstream target gene transcription. We explored whether Rev-Erbα regulates Rankl expression via direct binding to the Rankl promoter. First, we determined the characteristics of Rev-Erbα using the JASPAR database, including sequence logo (Figure 9A), frequency matrix (Figure 9B), TFFM first order summary logos (Figure 9C), and TFFM peak logo (Figure 9D). After that, we used the NCBI Gene database to determine the location of the promoter of Rankl, Chr 14:78545384–78,547,483. Next, the UCSC database was used to predict potential transcription factors that could target Rankl. Unfortunately, we found that Rev-Erbα was not included in the list of potential transcription factors of Rankl (Figure 9E). Finally, the JASPAR database was used again to analyse the
sequences of Rev-Erbα and the promoter of Rankl. Consistent with the UCSC database results, a total of 0 putative sites were predicted with a relative profile score threshold of 80% (Figure 9F).

3.10 | Enrichment analysis

The potential miRNAs that cooperate biological pathways always require collegial effects to bring about consolidated biological functions. Biological process and pathway analysis can make us a better understanding of miRNA function. Wordcloud of categories (top 100 by p-value) was shown in Figure 10A. In Figure 10B, miRNA/precursor to category heatmap (top 100 by p-value) was listed. Localization (RNALocate), Confidence (miRBase), Pubmed (miRBase), Chromosomal location (miRBase) and Family (miRBase) were exhibited from Figure 11A–O.

4 | DISCUSSION

Diabetes can lead to osteoporosis due to the high glucose environment inhibiting osteogenesis. Moreover, diabetes can promote osteoclastogenesis. These processes are closely associated with regulating RANKL/OPG expression and secretion under high
glucose concentrations. In MLO-Y4 cells, high glucose can promote the expression and secretion of RANKL and inhibit the expression and secretion of OPG. This is consistent with the results from a rat model of diabetic osteoporosis reported by Qi et al. and those obtained from human periodontal ligament fibroblasts and vascular smooth muscle cells. However, contradictory results have also been reported from a few studies. Qu et al. reported that high glucose inhibits osteoclastogenesis in osteoclast precursor cells isolated from Sprague-Dawley rats, while high glucose and palmitate (or ester) promote osteoclastogenesis. Similarly, Chang et al. suggested that high glucose reduces RANKL/OPG expression in vascular smooth muscle cells (A7r5) and causes vascular calcification.

Based on the reports that a high-glucose environment and biological rhythm influence each other, we proposed that high glucose may regulate RANKL/OPG expression by altering the biological rhythm and expression of Rev-Erbα. The existence of circadian rhythms has been reported in bone tissue, and bone disorders are associated with the occurrence of osteoporosis. Furthermore,
Rev-Erbα, as a circadian regulatory protein, is involved in the regulation of bone metabolism. Recent studies have shown that Rev-Erb inhibits osteogenic differentiation\textsuperscript{68–70} and suppresses osteoclast differentiation.\textsuperscript{69,71} These results suggest that Rev-Erb exhibits biological characteristics of a transcription inhibitor.\textsuperscript{71–78} However, our analysis using JASPAR and the UCSC database confirmed that Rev-Erbα regulates Rankl expression via indirect binding to the Rankl promoter, suggesting an underlying mechanism or signalling pathway between Rev-Erb and Rankl. Since osteoblasts and osteoclasts co-exist and interact to maintain bone homeostasis in vivo,\textsuperscript{79–81} the co-culture of osteoblasts and osteoclasts is a reliable model system to simulate the in vivo environment. Thus, the results obtained in our in vitro system are expected to translate to in vivo culture conditions but should be validated in animal models or primary cell culture-based systems in future studies.

However, in the present study, we mainly focused on MC3T3-E1/Raw264.7 cells co-culture system induced by high glucose in vitro and we think that in vitro experiment though not optimal, should be sufficient to draw the conclusion that melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev-Erbα in osteoblasts.

In this study, we focus on the fact that melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev-Erbα in osteoblasts. Rev-Erbα is not only a circadian clock protein, but also a target of the circadian hormone, melatonin. We think that no time course of expression, though not optimal, should be sufficient to conclude that melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev-Erbα in osteoblasts.

In the co-culture system, osteoblasts were not allowed cell-to-cell contact with RAW264.7 cells. Melatonin does have a direct impact on RAW264.7 cell viability or osteoclastogenesis. In the co-culture system, there is indeed such a role that melatonin does directly impact RAW264.7 cell viability or osteoclastogenesis. However, to demonstrate the change of RANKL/OPG in osteoblasts, we studied the molecular biology of the two kinds of cells and concluded that the addition of melatonin reduced RANKL/OPG in osteoblasts. It is well known that RANKL/OPG can promote osteoclast differentiation.

To the best of our understanding, certain prior studies have already provided an explanation for melatonin receptor.\textsuperscript{82} Moreover, in the present study, we primarily focused on the fact that melatonin inhibits osteoclastogenesis via RANKL/OPG suppression.
mediated by Rev-Erbα in osteoblasts. The obtained results revealed the conclusion, which comprehensively explains the issue at hand. The fact that no melatonin receptor related experiments have been conducted should suffice to draw conclusions, even though it is not ideal.

5 | CONCLUSION

High glucose promoted osteoclast differentiation in our osteoblast-osteoclast co-culture system, while melatonin partially reversed the high glucose effects. This suggested that melatonin may be beneficial in treating osteoporosis by inhibiting osteoclast differentiation. Moreover, we found that the melatonin-induced reversal was mediated by the mir-882/Rev-Erbα axis, which reduced the expression and secretion of RANKL/OPG in osteoblasts, thereby inhibiting osteoclastogenesis. This study provides a new theoretical basis for diabetic osteoporosis and reveals the potential of melatonin for treating diabetic osteoporosis by inhibiting osteoclastogenesis.

AUTHOR CONTRIBUTIONS
Yihao Tian: Conceptualization (lead). Jian Ming: Writing – review and editing (lead).

ACKNOWLEDGEMENTS
Thanks to the people who helped me.

CONFLICT OF INTEREST
The authors declare that the study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Yihao Tian https://orcid.org/0000-0001-8584-5480

REFERENCES
1. Rosenkranz RR. To advance population health, we need to be "well behaved": the science of health behaviour change. Stud Health Technol Inform. 2020;268:1-13. doi:10.3233/SHTI200002
2. Kanazawa TI, Takeno A, Tanaka KI, Yamane Y, Sugimoto T. Osteoporosis and vertebral fracture are associated with deterioration of ADL and QOL in patients with type 2 diabetes independently of other diabetic complications. Diabetologia. 2017;60:5557-5558.
3. Lee HS, Hwang JS. Impact of type 2 diabetes mellitus and antidiabetic medications on bone metabolism. Curr Diabetes Rep. 2020;20:78. doi:10.1007/s11892-020-01361-5
4. Martínez-Villanueva M, Ramirez-Ruiz C, Hernández-Martínez AM, Noguera-Velasco JA. Diabetes and osteoporosis, study of polymorphisms. Clin Chim Acta. 2019;493:S167. doi:10.1016/j.cca.2019.03.348
5. Cheng YZ, Yang SL, Wang JY, et al. Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway. Life Sci. 2018;205:184-192. doi:10.1016/j.lfs.2018.04.042
6. Yanan A, Haiying Z, Chao W, et al. Activation of ROS/MAPKs/NF-kappaB/NLRP3 and inhibition of effecoryctosis in osteoclast-mediated diabetic osteoporosis. FASEB J. 2019;33:12515-12527. doi:10.1096/fj.201802805RR
7. Rharass T, Lucas S. High glucose level impairs human mature bone marrow adipocyte function through increased ROS production. Front Endocrinol. 2019;10:607. doi:10.3389/fendo.2019.00607
8. Yamagishi S, Nakamura K, Inoue H. Possible participation of advanced glycation of proteins in the pathogenesis of osteoporosis in diabetic patients. Med Hypo. 2005;65:1013-1015. doi:10.1016/j.mehy.2005.07.017
9. Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets. 2011;12:2096-2102. doi:10.2174/138945011798829456
10. Eckhardt BA, Rowsey JL, Thicke BS, et al. Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes. JCI Insight. 2020;5:e135236. doi:10.1172/jci.insight.135236
11. Vasishth D, Gibson GJ, Khoury J, Schaffer MB, Kimura J, Fyhrie DP. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone. 2001;28:195-201. doi:10.1016/s8756-3282(00)00434-8
12. Xie H, Tang SY, Luo XY, et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int. 2007;80:201-210. doi:10.1007/s00223-006-0155-7
13. Avnet S, Perut F, Salerno M, Sciaccia L, Baldini N. Insulin receptor isoforms are differently expressed during human osteoclastogenesis. Differentiation. 2012;83:242-248. doi:10.1016/j.diff.2012.02.002
14. Thralkill K, Bunn RC, Lumpkin C, et al. Loss of insulin receptor in osteoprogenitor cells impairs structural strength of bone. J Diabetes Res. 2014;703589. doi:10.1155/2014/703589
15. okazaki R, totsuka Y, hamano K, et al. metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab. 1997;82:2915-2920. doi:10.1210/jcem.82.9.4258
16. Paschoiu SA, vryonidou A. diabetes mellitus and osteoporosis. Minerva Endocrinol. 2019;44:333-335. doi:10.23736/S0391-1977.19.03040-2
17. Zhang WL, Meng HZ, Yang RF, et al. melatonin suppresses autophagy in type 2 diabetic osteoporosis. Oncotarget. 2016;7:52179-52194. doi:10.18632/oncotarget.10538
18. jing HF, Wang XM. effects of aerobic exercise combined with melatonin on osteoporosis of type II diabetic rats. Zhongguo Ying Yong Sheng Li Xue Za Zhi Zhongguo Yingyong Shenglixue Zazhi. 2017;33:252-256. doi:10.2047/j.4jcp.5395.2017.062
19. munmun M, Witt-enderby PA. melatonin effects on bone: implications for use as a therapy for managing bone loss. J Pineal Res. 2021;1(71):e12749. doi:10.1111/jpi.12749
20. Sharan K, Lewis K, Furukawa T, Yadav VK. Regulation of bone mass through pineal-derived melatonin-MT2 receptor pathway. J Pineal Res. 2017;63:e12423. doi:10.1111/jpi.12423
21. Juhnevica-Radenkova K, Moreno DA, Ikase L, Drudze I, Radenkova V. Naturally occurring melatonin: sources and possible ways of its biosynthesis. Compr Rev Food Sci Food Saf. 2020;19:4008-4030. doi:10.1111/1541-4337.12639
22. Lazar MA. Rev-erbs. Integrating Metabolism around the Clock A Time for Metabolism and Hormones. Cham (CH). 2016:63-70.
23. amador A, kamenecka TM, Solt LA, Burris TP. REV-ERBJ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009. Biochem Pharmacol. 2018;150:1-8. doi:10.1016/j.bcp.2018.01.009
24. Ohba Y, Tei H. Phosphorylation of N-terminal regions of REV-ERBs regulates their intracellular localization. Genes Cells Devoted Mol Cell Mech. 2018;23(4):285-293. doi:10.1111/gtc.12571

25. Lam MT, Cho H, Lesch HP, et al. REV-Erb repress macrophage gene expression by inhibiting enhancer-directed transcription. Nature. 2013;498:511-515. doi:10.1038/nature12209

26. Muscat GEO, Burke LJ, Downes M. The corepressor N-CoR and its variants RIP13a and RIP13delta1 directly interact with the basal transcription factors TFIIB, TAFII32 and TAFII70. Nucleic Acids Res. 1998;26:2899-2907. doi:10.1093/nar/26.26.2899

27. Solt LA, Kojetin DJ, Burris TP. The REV-ERBs and RORS: molecular links between circadian rhythms and lipid homeostasis. Future Med. Chem. 2011;3:623-638. doi:10.4155/fmc.11.19

28. Ohba Y, Tei H. Phosphorylation of N-terminal regions of REV-ERBs regulates tumor necrosis factor-induced expression of proinflammatory molecules in C6 astroglial cells. Biochem Biophys Res Commun. 2016;469:151-157. doi:10.1016/j.bbrc.2015.11.086

29. Ripperger JA, Albrecht U. REV-ERB-erating nuclear receptors: function in circadian metabolism and physiology. Cell Res. 2012;22:1319-1321. doi:10.1038/cr.2012.81

30. Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012;485:62-68. doi:10.1038/nature11030

31. Angelou E, Nasiri-Ansari N, Karapanagioti A, et al. Expression of clock-related genes in benign and malignant adrenal tumors. Endocrine. 2020;68:650-659. doi:10.1007/s12020-020-02242-z

32. Wagner PM, Monjes NM, Guido ME. Chemotherapeutic effect of SR9009, a REV-ERB agonist, on the human glioblastoma T98G cells. ASN Neuro. 2019;11:1759091419892713. doi:10.1177/1759091419892713

33. Chang C, Loo CS, Zhao X, et al. The nuclear receptor REV-ERBα modulates Th1 cell-mediated autoimmune disease. Proc Natl Acad USA. 2019;116:18528-18536. doi:10.1073/pnas.1907563116

34. Zhuang X, Magri A, Hill M, et al. The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication. Nat Commun. 2019;10:377. doi:10.1038/s41467-019-08299-7

35. Gong Z, Da W, Tian Y, et al. Exogenous melatonin prevents type 1 diabetes mellitus-induced bone loss, probably by inhibiting senescence. Osteoporos Int. 2022;33:453-466. doi:10.1007/s00198-021-06061-8

36. Da H, Wang X, Zhang W, et al. Melatonin suppresses ferroptosis induced by high glucose via activation of the Nrf2/HO-1 signaling pathway in type 2 diabetic osteoclasts. Eur J Pharmacol. 2020;860/03008207.2017.1290085

37. Sun T, Yan Z, Cai J, et al. Effects of mechanical vibration on cell morphology, proliferation, apoptosis, and cytokine expression/secretion in osteocyte-like MLO-Y4 cells exposed to high glucose. Cell Biol Int. 2019. doi:10.1002/cbin.11221

38. Qi S, He J, Han H, et al. Anthocyanin-rich extract from black rice (Oryza sativa L. japonica) ameliorates diabetic osteoporosis in rats. Food Funct. 2019;10:5350-5360. doi:10.1039/c9fo00681h

39. Zhang L, Ding Y, Rao GZ, Miao D. Effects of IL-10 and glucose on expression of OPG and RANKL in human periodontal ligament fibroblasts. Braz J Med Biol Res. 2016;49:e4324. doi:10.1590/1419-448X20154324

40. Kang YH, Jin JS, Sun SM. Long term effect of high glucose and phosphate levels on the OPG/RANK/RANKL/TRAIL system in the progression of vascular calcification in rat aortic smooth muscle cells. Korean J Physiol Pharmacol. 2015;19:111-118. doi:10.4196/kjp.2015.19.2.111

41. Qu B, Gong K, Yang H, et al. SIRT1 suppresses high glucose and palmitate-induced osteoclast differentiation via deacetylating p65Shc. Mol Cell Endocrinol. 2018;474:97-104. doi:10.1016/j.mce.2018.02.015

42. Ke D, Banerjee D, Bose S. In vitro characterization of Si4+ and Zn2+ doped plasma sprayed hydroxyapatite coatings using osteoblast and osteoclast co-culture. ACS Biomater Sci Eng. 2019;5:1302-1310. doi:10.1021/acsbiomaterials.8b01553

43. Chen X, Wang Z, Duan N, Zhu G, Schwarz EM, Xie C. Osteoblast-osteoclast interactions. Connect Tissue Res. 2018;59:99-107. doi:10.1080/03008207.2017.1290085

44. Han Y, You X, Xing W, Zhang Z, Zou W. Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. Bone Res. 2018;6:16. doi:10.1038/s41413-018-0019-6

45. Jacome-Galarza CE, Percin GI, Muller JT, et al. Developmental origin, functional maintenance and genetic rescue of osteoclasts. Nature. 2019;568(7753):541-545. doi:10.1038/s41586-019-1105-7

46. Wang Y, Wang J, Moore DC, et al. Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signaling. Nature. 2013;499(7459):491-495. doi:10.1038/nature12396

47. Calipaperoumal G, Souyet M, Besidhoum M, Petite H, Anagnostou F. Type 2 diabetes impairs angiogenesis and osteogenesis in calvarial defects: MicroCT study in ZDF rats. Bone. 2018;112:161-172. doi:10.1016/j.bone.2018.04.009

48. Tang Y, Zheng L, Zhou J, et al. miR-203-3p participates in the suppression of diabetes-associated osteogenesis in the jaw bone through targeting Smad1. Int J Mol Med. 2018;41:1595-1607. doi:10.3892/ijmm.2018.3373

49. Melekhovets OK, Tovazhnyanska VD, Yakovtsova II. Effects of diabetes mellitus on reparative osteogenesis. Wiad Lek. 2019;72:1723-1726.

50. Kawashima Y, Fritton JC, Yakar S, et al. Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone. 2009;44:648-655. doi:10.1016/j.bone.2008.12.012

51. Iitsuka N, Hie M, Tsukamoto I. Zinc supplementation inhibits the increase in osteoclastogenesis and decrease in osteoblastogenesis in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2013;714:41-47. doi:10.1016/j.ejphar.2013.05.020

52. Reni C, Mangialardi MG, Meloni M, Madeddu P. Diabetes stimulates osteoclastogenesis by acidosis-induced activation of transient receptor potential cation channels. Sci Rep. 2016;6:30639. doi:10.1038/srep30639
60. Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. *Am J Physiol Gastrointest Liver Physiol*. 2020;318:G554-G573. doi:10.1152/ajpgi.00223.2019

61. de Luis DA, Izaola O, Primo D, Aller A. A circadian rhythm-related MTNR1B genetic variant (rs10830963) modulates body weight change and insulin resistance after 9 months of a high protein/low carbohydrate diet. *Diabetes Complications*. 2020;34:107534. doi:10.1016/j.dci.2020.107534

62. Mason IC, Qian J, Adler GK, Scheer FAJL. Impact of circadian disruption on glucose metabolism: implications for type 2 diabetes. *Diabetologia*. 2020;63:462-472. doi:10.1007/s00125-019-05059-6

63. Bukowska-Damska A, Skowronska-Jozwiak E, Peplonska B. Night shift work and osteoporosis: evidence and hypothesis. *Chronobiol Int*. 2019;36:171-180. doi:10.1080/07420528.2018.1528553

64. Gonçalves CF, Meng QJ. Timing metabolism in cartilage and bone: links between circadian clocks and tissue homeostasis. *J Endocrinol*. 2019;243(3):R29-R46. doi:10.1530/JOE-19-0256

65. Li G, Zhang L, Wang D, et al. Muscle-bone crosstalk and potential therapies for sarcopenia-osteoporosis. *J Cell Biochem*. 2019;120:14262-14273. doi:10.1002/jcb.28946

66. Montes Castillo MC, Martínez Ramírez MJ, Soriano Arroyo R, et al. Glucagon-like peptide 1 and glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women. *Sci Rep*. 2019;9:13651. doi:10.1038/s41598-019-50117-z

67. Schiellerup SP, Skov-Jeppesen K, Windelev JA, et al. Gut hormones and their effect on bone metabolism. Potential Drug Therapies for Future Osteoporosis Treatment. *Front Endocrinol*. 2019;10:75. doi:10.3389/fendo.2019.00075

68. He CY, Lin FY. Overexpression of the circadian clock gene rev-erba affects murine bone mesenchymal stem cell proliferation and osteogenesis. *Stem Cells Dev*. 2015;24:1194-1204. doi:10.1089/scd.2014.0437

69. Kim K, Kim JH, Kim I, Seong S, Kim N. Rev-erba negatively regulates osteoclast and osteoblast differentiation through p38 MAPK signaling pathway. *Mol Cells*. 2020;43:34-47. doi:10.14348/molcells.2019.0232

70. Fu-wei L, Xiao-mei X, Yan C, Yi-jia X, Qing Z. Roles of rev-erba alphya and Ror alpha in osteoblastogenesis of mouse bone marrow mesenchymal stem cells. *Chin J Tissue Eng Res*. 2018;22:2625-2630. doi:10.3969/j.issn.2095-4344.0848

71. Song C, Tan P, Zhang Z, et al. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation. *FASEB J*. 2018;32:3215-3228. doi:10.1096/fj.201600825RRR

72. Pardee KL, Xu X, Reinking J, et al. The structural basis of gas-responsive transcription by the human nuclear hormone receptor REV-ERBBeta. *PLoS Biol*. 2009;7:e43. doi:10.1371/journal.pbio.1000043

73. Crumbley C, Burris TP. Direct regulation of CLOCK expression by REV-ERB. *PLoS One*. 2011;6:e17290. doi:10.1371/journal.pone.0017290

74. Chandra V, Mahajan S, Saini A, et al. Human IL10 gene repression by rev-erb alpha ameliorates mycobacterium tuberculosis clearance. *J Biol Chem*. 2013;288:10692-10702. doi:10.1074/jbc.M113.455915

75. Li T, Eheim AL, Klein S, et al. Novel role of nuclear receptor rev-erb alpha in hepatic stellate cell activation: potential therapeutic target for liver injury. *Hepatology*. 2014;59:2383-2396. doi:10.1002/hep.27049

76. Vaisiére A, Berger S, Harrus D, et al. Molecular mechanisms of transcriptional control by rev-erbx: an energetic foundation for reconciling structure and binding with biological function. *Protein Sci Publ Protein Soc*. 2015;24:1129-1146. doi:10.1074/pro.2015.729120

77. Jager J, Wang F, Fang B, et al. The nuclear receptor rev-erb alpha regulates adipose tissue-specific FGF21 signaling. *J Biol Chem*. 2019;291:10867-10875. doi:10.1074/jbc.M116.719120

78. Ikeda R, Tsuchiya Y, Koike N, et al. REV-ERBalpha in hepatic stellate cell activation: potential therapeutic target for liver injury. *Hepatology*. 2020;63:462-472. doi:10.1002/hep.27049

79. Maria S, Samsonraj RM, Munmun F, et al. Biological effects of melatonin on osteoblast/osteoclast co-cultures, bone, and quality of life: implications of a role for MT2 melatonin receptors, MEK1/2, and MEK5 in melatonin-mediated osteoblastogenesis. *J Pineal Res*. 2019;64:e12465. doi:10.1111/jpi.12465

80. Forte L, Sarda S, Torricelli P, et al. Multifunctionalization modulates hydroxyapatite surface interaction with bisphosphonate: antosteoporotic and antioxidantive stress materials. *ACS Biomater Sci Eng*. 2019;5:3429-3439. doi:10.1021/acsbiomater.9b00779

81. He F, Bai J, Wang J, Zhai J, Tong L, Zhu G. Irradiation-induced osteoarthritis: role of TNFR1 and MEK5 in melatonin- mediated osteoclastogenesis. *Sci Rep*. 2019;9:10171. doi:10.1038/s41598-019-46656-0

82. Kim HJ, Kim HJ, Bae M-K, Kim Y-D. Suppression of osteoclastogenesis by melatonin: a melatonin receptor-independent action. *Int J Mol Sci*. 2017;18(6):1142. doi:10.3390/ijms18061142

**How to cite this article:** Tian Y, Ming J. Melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev-Erbα in osteoblasts. *J Cell Mol Med*. 2022;26:4032-4047. doi:10.1111/jcmm.17440